Loading
KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming subunit of the voltage-gated potassium (Kv) channel broadly expressed in brain and involved in the regulation of neuronal excitability. Associates with KCNQ3/Kv7.3 pore-forming subunit to form a potassium channel which contributes to M-type current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons. Contributes, with other potassium channels, to the molecular diversity of a heterogeneous population of M-channels, varying in kinetic and pharmacological properties, which underlie this physiologically important current.
Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes literature 0.74, genetic association 0.48, somatic mutation 0.23, clinical 0.76).
In plain words · KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming subunit of the voltage-gated potassium (Kv) channel broadly expressed in brain and involved in the regulation of neuronal excitability.
No product in this corpus aims at KCNQ5 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCNQ5: RNA group enriched (bone marrow 4 nTPM, brain 13 nTPM, skeletal muscle 15 nTPM); high antibody staining in 1 normal tissue. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KCNQ5 tissue; Open Targets ENSG00000185760 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Lerche et al, J. Biol. Chem, 2000, "Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity". Source.
Sources: HGNC HGNC:6299 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NR82 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000185760 (association with cancer (MONDO_0004992) 0.57; (GraphQL API, CC0))
Pore-forming subunit of the voltage-gated potassium (Kv) channel broadly expressed in brain and involved in the regulation of neuronal excitability. Associates with KCNQ3/Kv7.3 pore-forming subunit to form a potassium channel which contributes to M-type current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons. Contributes, with other potassium channels, to the molecular diversity of a heterogeneous population of M-channels, varying in kinetic and pharmacological properties, which underlie this physiologically important current. Also forms a functional channel with KCNQ1/Kv7.1 subunit that may contribute to vasoconstriction and hypertension. Channel may be selectively permeable in vitro to other cations besides potassium, in decreasing order of affinity K(+) = Rb(+) > Cs(+) > Na(+). Similar to the native M-channel, KCNQ3-KCNQ5 potassium channel is suppressed by activation of the muscarinic acetylcholine receptor CHRM1. Location: Cell membrane (UniProt). Locus 6q13 (HGNC).
RNA: group enriched (bone marrow 4 nTPM, brain 13 nTPM, skeletal muscle 15 nTPM, thyroid gland 4 nTPM, tongue 11 nTPM), detected in some normal tissues.
Medium: Cerebral cortex.
No cancer stained high; medium in colorectal cancer, glioma, liver cancer, lung cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KCNQ5" OR ABSTRACT:"KCNQ5" OR TITLE:"potassium voltage-gated channel subfamily Q member 5" OR ABSTRACT:"potassium voltage-gated channel subfamily Q member 5" OR TITLE:"Potassium voltage-gated channel subfamily KQT member 5" OR ABSTRACT:"Potassium voltage-gated channel subfamily KQT member 5" OR TITLE:"Kv7.5" OR ABSTRACT:"Kv7.5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNQ5, not a curated reading list.